Nutra Pharma Has Announced That They Have Engaged Medical strategy Consultants LLC to Aid in the Creation and Filing of Orphan Drug Applications With the US Food and Drug Administration CORAL SPRINGS, FL–(Marketwired – May 26, 2015) – Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human […]
Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
For the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.
Pharma continues to lag behind the consumer space in the use of mobile marketing technologies, but the steady advance of consumer tech giants Google and Amazon into the healthcare space means that the industry will have to adapt the tools of AI, voice and chatbots into their marketing, just as their consumer brethren already have.
Intouch Solutions’ Sean Hartigan and Heartbeat’s David Sakadelis say their pharma clients are skittish about the use of chatbots and AI, with an understanding of these technologies more influenced by the grim future of Skynet in the “Terminator” movie franchise rather than the reality of where AI is right now.
In the initial excitement over the possibilities of mobile marketing, pharma rushed to create its own apps. And then these apps languished.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Augmented reality (AR) gained widespread attention the summer of 2016 with the addictive game Pokémon Go. But these days, AR is not just for fun. This disruptive technology is expected to drive significant changes to businesses across many industries because of its ability to combine the virtual and physical worlds.
Augmented reality (AR) and virtual reality (VR) have experienced incredible growth since 2013, when the first Oculus Rift VR headset hit the market and provided a whole new sense of what was possible.
Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Pharma marketers must listen to their customers and find ways to smooth the patient journey if they are to create effective customer experiences and create loyalty beyond the first prescription.
Consumer/Patient Experience Special Feature: Digital therapeutics – Improving the patient experience at scale
It’s no surprise that the patient experience with the healthcare system often leads to frustration and despair. With chronic disease affecting around 50 percent of the U.S. population, it puts into perspective the sheer volume of patient experiences that are being generated each day and the magnitude of the problems that need solving. The high cost of therapies, the long wait to see a physician, the administrative burden of getting a prior authorization…the list goes on. But the day is coming, and in some cases it’s already here, where a patient could have a robust health system right in their pocket.
Consumer/Patient Experience Special Feature: Masters Of The Pharma Universe: 4 Databases Every Digital Marketer Must Know
Nearly two-thirds of U.S. senior business decision-makers rank big data/analytics first among the technologies necessary for enhancing the customer experience. A similar number put “improving data analysis capabilities” at the top of their priorities.
The names of the tools may be changing, but the goal for brand managers remains the same in 2018: getting as close as possible to real patients and their needs.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
Bavarian Nordic is hot property after striking two big vaccine deals but the small Danish company is not for sale, despite a wave of consolidation in the healthcare industry, its chief told Reuters. Best known before for selling smallpox vaccine to governments worried about biosecurity, Bavarian’s share price has tripled after signing deals […]
SAN DIEGO, May 27, 2015 (BUSINESS WIRE) — Retrophin, Inc. RTRX, +9.56% today announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher (“Pediatric PRV”) to Sanofi SNY, +1.08% Retrophin received the Pediatric PRV when Cholbam™ was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric and adult […]
Power can come from all kinds of industries and sectors, from politics and investing to media and even fashion. But one thing all the women on FORBES’ 12th list of 100 Most Powerful Women have in common is brainpower. Seven of those brainy women have roots in science and health, although they work in a […]
NeoStem Inc recently received a grant of $17.7 million to fund the company’s effort in research of cell therapy products for cancer from California Institute of Regenerative Medicine. Following the announcement of the grant, shares of NeoStem rose by over 20 percent. NeoStem CEO Dr. David Mazzo was on Fox Business News recently to talk […]
AstraZeneca’s (AZN.L) hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. Amgen (AMGN.O), its partner on the project, announced late on Friday it was ending a collaboration to develop brodalumab […]
The purging of the old guard installed by former chief exec Chris Viehbacher continued at French drugmaker Sanofi (SNY) Monday, when the firm’s global head for prostate cancer drug Jevtana, Zhen Su, left to find work outside the company. The company did not issue a release on Su’s departure but the press learned about it […]
Despite sagging stock prices, major investors in U.K.-based GlaxoSmithKline (GSK) indicated yesterday they are willing to give company CEO Andrew Witty time to turn the company’s fortunes around—but probably not too much time. GSK did not respond to a request for a statement in time for deadline. The Financial Times reported that shareholders have decided […]
THOUSAND OAKS, Calif., May 22, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the Company has commenced termination of its participation in the co-development and commercialization of brodalumab with AstraZeneca (LON:AZN, STO:AZN and NYSE:AZN). Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The decision was […]
When drugs cost $1,000 a pill or $25,000 for a year of injections, insurers and employers want to make sure these prescriptions are being taken at the right place and at the right time and have the right outcome for the patient. After all, trends in insurance payment from private insurers as well as government […]